Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 19/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | KDM5C | P41229 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14067364 | 0.84 | APP (0.67) | APPKDM4EMEN1NPC1MITF | |
| SCHEMBL3431380 | 0.84 | APP (0.67) | APPKDM4EMEN1NPC1MITF | |
| SCHEMBL14067366 | 0.84 | APP (0.67) | APPKDM4EMEN1NPC1MITF | |
| SCHEMBL23753400 | 0.83 | APP (0.44) | APPKDM4EMEN1NPC1MITF | |
| SCHEMBL3305627 | 0.82 | APP (0.68) | APPKDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL21566064 | 0.79 | APP (0.67) | APPKDM4EMEN1NPC1MITF | |
| SCHEMBL30232538 | 0.78 | ALDH1A1 (0.42) | APPKDM4EMEN1NPC1MITF | |
| SCHEMBL21566129 | 0.78 | ALDH1A1 (0.42) | APPKDM4EMEN1NPC1MITF | |
| SCHEMBL3300710 | 0.78 | ALDH1A1 (0.61) | APPKDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL2127350 | 0.77 | APP (0.69) | APPKDM4EMEN1NPC1MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100092385-A1 | Novel Heteroaryl Substituted Imidazo [1,2-A] Pyridine Derivatives | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | claimed |
| EP-2125800-A1 | NOVEL HETEROARYL SUBSTITUTED IMIDAZO Ý1,2 -A¨PYRIDINE DERIVATIVES | AstraZeneca AB (SE) | 2009-12-02 | — | — | EP | claimed |
| WO-2008091195-A1 | NOVEL HETEROARYL SUBSTITUTED IMIDAZO [1,2 -A] PYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | WO | claimed |
| US-20100092385-A1 | Novel Heteroaryl Substituted Imidazo [1,2-A] Pyridine Derivatives | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100092385-A1 | Novel Heteroaryl Substituted Imidazo [1,2-A] Pyridine Derivatives | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| WO-2009121330-A2 | ILLUMINATION DEVICE | OSRAM OPTO SEMICONDUCTORS GMBH (DE) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092385-A1 | Novel Heteroaryl Substituted Imidazo [1,2-A] Pyridine Derivatives | APP, PSEN1, PSEN2 | APP 1/4885KDM4E 3283/4885MEN1 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.